Pharmacokinetic, Pharmacodynamic, Preclinical and Clinical Models for Evaluation of Nanoparticles

Pharmacokinetic (PK) and pharmacodynamic (PD) models are essential tools for the evaluation of nanoparticles in both preclinical and clinical settings [1]. PK models focus on ADME of nanoparticles within the body, providing insights into their biodistribution, clearance rates, and potential accumulation in specific tissues [2]. These models help determine optimal dosing regimens, predict drug concentrations at target sites, and estimate the systemic exposure of nanoparticles. Compartmental modeling involves describing the body as a series of interconnected compartments, each representing a specific physiological space where the drug or nanoparticle distributes. Compartmental models assume that the distribution and elimination processes can be approximated using exponential equations. This approach is suitable for understanding the overall behavior of nanoparticles in different body compartments. In the context of nanoparticles, compartments represent different tissues, organs, or physiological spaces where nanoparticles accumulate. Parameters in the model include transfer rates between compartments, volumes of distribution, and elimination rates [3, 4]. However, compartmental modeling may oversimplify the complex behavior of nanoparticles, especially when considering their unique interactions with biological components. Non-compartmental modeling involves direct analysis of concentration-time profiles without assuming a specific compartmental structure. This approach is often used when the pharmacokinetics of nanoparticles do not fit well into compartmental models due to their complex behaviour [3]. In non-compartmental modeling, various pharmacokinetic parameters are calculated directly from the observed concentration-time data. These parameters include area under the concentration-time curve (AUC), maximum concentration (Cmax), time to reach Cmax (Tmax), and terminal half-life. Non-compartmental modeling is useful for nanoparticles when the distribution and elimination processes are not well-characterized by a simple compartmental model. It provides a more flexible way to understand nanoparticle behavior in vivo [5]. The choice between compartmental and non-compartmental modeling depends on the specific behavior of the nanoparticles being studied and the availability of the in-vitro data [6].